Fig. 3From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital schoolAcceptability curve of the Markov model comparing the strategies XELOX and XELOX plus bevacizumab used in the first line in the treatment of patients with metastatic colorectal cancerBack to article page